Thermo Fisher and Siemens Healthcare Diagnostics renew their
non-exclusive, long-term, royalty-bearing agreement for the use of
Thermo Fisher’s Procalcitonin (B·R·A·H·M·S PCT™) technology, currently
available as an automated immunoassay on the Siemens ADVIA Centaur® XP
and CP systems in all countries outside the United States and China. The
agreement extends a long-standing relationship between the companies.
ADVIA Centaur® B·R·A·H·M·S PCT™ immunoassay currently offers clinicians
an integrated solution for accurately diagnosing sepsis and monitoring
response to antibiotic therapy allowing for improved clinical decision
making. The ADVIA Centaur® systems have a large global installed base in
hospital clinical laboratories.
The PCT biomarker test is the gold standard for the early detection of sepsis in critically ill patients and is recommended to initiate, monitor and discontinue antibiotic treatment in the presence of relevant bacterial infections. Broader availability of PCT testing will lead to improved hospital management and care of patients with sepsis or at high risk of developing it.
“The continuation of our close collaboration with Siemens significantly
increases the global reach of this critical biomarker, making it
available to a broader patient population,” said Marc Tremblay,
president of Thermo Fisher Scientific’s Clinical Diagnostics division.
“The key for preventing sepsis is the early diagnosis of infections.
Early diagnosis also reduces the health economic burden of sepsis
therapy, a medical condition that is still very common today and
accounts for hundreds of thousands of deaths each year. Therefore, PCT
supports hospitals in optimizing their service levels and cost
effectiveness in today’s challenging economic environment.”
The worldwide number of patients affected by sepsis is estimated to be
20 to 30 million annually and claims more lives than bowel and breast
cancer combined1. Despite advances in modern medicine,
including antibiotics and vaccines, sepsis remains the primary cause of
death from infection with hospital mortality rates between 30 to 60%1.
Hospital costs to treat severe sepsis in the U.S. are estimated at $16
billion dollars annually2. Much of this cost is attributed to
misdiagnosis or delayed diagnosis, making rapid, more reliable detection
a national, if not global, imperative. Research published in Critical
Care Medicine showed that each hour of delay in therapy can decrease
chances of patient survival by 7.6 percent3.
Source: Thermo Fisher Scientific Inc.